Cleveland Biolabs, Inc. (CBLI) Posts Wider than Expected Q2 Loss

Cleveland Biolabs, Inc. (NASDAQ: CBLI) reported Q2 EPS of ($0.14), $0.10 worse than the analyst estimate of ($0.04).

For earnings history and earnings-related data on Cleveland Biolabs, Inc. (CBLI) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Investing.com’s stocks of the week
• Piper Sandler on Virtu Financial (VIRT): 'The most overlooked name in our coverage'